BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 31419130)

  • 21. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2017 Jun; 18(6):36. PubMed ID: 28534251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.
    Zhao D; Chen J; Chu M; Long X; Wang J
    Drug Des Devel Ther; 2020; 14():1663-1681. PubMed ID: 32431491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological and clinical properties of lorlatinib in the treatment of
    El Darsa H; Abdel-Rahman O; Sangha R
    Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK inhibitors, resistance development, clinical trials.
    Rothenstein JM; Chooback N
    Curr Oncol; 2018 Jun; 25(Suppl 1):S59-S67. PubMed ID: 29910648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
    Wong KM; Noonan S; O'Bryant C; Jimeno A
    Drugs Today (Barc); 2015 Mar; 51(3):161-70. PubMed ID: 25876560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic strategies in advanced ALK positive non-small cell lung cancer].
    Tiotiu A; Billon Y; Vaillant P; Menard O; Hofman P; Mascaux C
    Rev Mal Respir; 2019 Dec; 36(10):1107-1116. PubMed ID: 31727555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review).
    Wang L; Wang W
    Oncol Rep; 2021 Jan; 45(1):13-28. PubMed ID: 33200229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
    Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives.
    Ryser CO; Diebold J; Gautschi O
    Curr Opin Oncol; 2019 Jan; 31(1):8-12. PubMed ID: 30394941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
    Tabbò F; Passiglia F; Novello S
    Curr Oncol Rep; 2021 Jan; 23(1):10. PubMed ID: 33387080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
    Iams WT; Lovly CM
    Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Straughan DM; Azoury SC; Shukla V
    Curr Drug Targets; 2016; 17(6):739-45. PubMed ID: 26073862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.
    Serritella AV; Bestvina CM
    Thorac Surg Clin; 2020 May; 30(2):137-146. PubMed ID: 32327172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
    Singhi EK; Horn L
    Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database.
    Zhou Z; Wang C; Ying L; Jin M; Zhang F; Shi D
    J Clin Pharm Ther; 2021 Aug; 46(4):1148-1154. PubMed ID: 33768534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?
    Wrona A
    Cancer Radiother; 2019 Sep; 23(5):432-438. PubMed ID: 31331844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Gadgeel SM
    Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.